Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.72 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.72 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.72 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.72 |
| ▸ | STAT3 | P40763 | 2/20 | 0.72 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.72 |
| ▸ | RELA | Q04206 | 2/20 | 0.72 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.72 |
| ▸ | APP | P05067 | 3/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.70 |
| ▸ | CA12 | O43570 | 2/20 | 0.70 |
| ▸ | CA1 | P00915 | 2/20 | 0.70 |
| ▸ | CA2 | P00918 | 2/20 | 0.70 |
| ▸ | CA3 | P07451 | 2/20 | 0.70 |
| ▸ | PKM | P14618 | 2/20 | 0.70 |
| ▸ | CA4 | P22748 | 2/20 | 0.70 |
| ▸ | CA6 | P23280 | 2/20 | 0.70 |
| ▸ | CA5A | P35218 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3858935 | 0.92 | KMT2A (0.66) | KMT2ACYP2D6NFKB1CYP1A2ALOX5 | |
| SCHEMBL3858939 | 0.92 | KMT2A (0.66) | KMT2ACYP2D6NFKB1CYP1A2ALOX5 | |
| SCHEMBL8965766 | 0.91 | CYP2D6 (0.72) | KMT2ACYP2D6NFKB1CYP1A2ALOX5 | |
| SCHEMBL8965757 | 0.91 | CYP2D6 (0.72) | KMT2ACYP2D6NFKB1CYP1A2ALOX5 | |
| SCHEMBL3125899 | 0.88 | KMT2A (1.00) | KMT2ACYP2D6NFKB1CYP1A2NFE2L2 | |
| SCHEMBL3125894 | 0.88 | KMT2A (1.00) | KMT2ACYP2D6NFKB1CYP1A2NFE2L2 | |
| SCHEMBL27779110 | 0.87 | CYP2D6 (0.67) | KMT2ACYP2D6NFKB1CYP1A2ALOX5 | |
| SCHEMBL20585531 | 0.87 | CYP2D6 (0.70) | KMT2ACYP2D6NFKB1CYP1A2ALOX5 | |
| SCHEMBL22618575 | 0.86 | APP (0.66) | KMT2ACYP2D6NFKB1CYP1A2ALOX5 | |
| SCHEMBL8964899 | 0.85 | APP (0.69) | KMT2ACYP2D6NFKB1CYP1A2ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11332427-B2 | Menaquinol compositions and methods of treatment | Epizon Pharma, Inc. (US) | 2022-05-17 | — | — | US | disclosed |
| US-20210009494-A1 | Menaquinol Compositions and Methods of Treatment | Epizon Pharma, Inc. (US) | 2021-01-14 | — | — | US | disclosed |
| US-10822295-B2 | Menaquinol compositions and methods of treatment | Epizon Pharma, Inc. (US) | 2020-11-03 | — | — | US | disclosed |
| WO-2014087331-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF EPILEPSY AND NEUROLOGIC DISEASES | KANDULA MAHESH (IN) | 2014-06-12 | — | — | WO | disclosed |
| US-8093427-B2 | Construction and screening of solution-phase derived library of fenbufen and ethacrynic acid | NATIONAL TSING HUA UNIVERSITY (TW) | 2012-01-10 | — | — | US | disclosed |
| US-20110306668-A1 | CONSTRUCTION AND SCREENING OF SOLUTION-PHASE DERIVED LIBRARY OF FENBUFEN AND ETHACRYNIC ACID | NATIONAL TSING HUA UNIVERSITY (TW) | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009494-A1 | Menaquinol Compositions and Methods of Treatment | SDHA, SDHB, NDUFB7 | KMT2A 1019/4885CYP2D6 1200/4885NFKB1 3055/4885 |
| US-11332427-B2 | Menaquinol compositions and methods of treatment | SDHA, SDHB, NDUFB7 | KMT2A 1019/4885CYP2D6 1200/4885NFKB1 3055/4885 |
| US-10822295-B2 | Menaquinol compositions and methods of treatment | PROC, VKORC1L1, VKORC1 | KMT2A 2145/4885CYP2D6 2380/4885NFKB1 726/4885 |
| US-20110306668-A1 | CONSTRUCTION AND SCREENING OF SOLUTION-PHASE DERIVED LIBRARY OF FENBUFEN AND ETHACRYNIC ACID | CYP4F2, ACR, CYP4F3 | KMT2A 4174/4885CYP2D6 82/4885NFKB1 1302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.